Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban vs Enoxaparin for VTE Prevention in Japanese THR Patients
NCT01205932Phase 3Completed
- Sponsor
- Bayer
- Start
- Sep 2010
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rivaroxaban in venous thromboembolism (VTE) (4 arms), sponsored by Bayer. Primary endpoints: Composite of any deep vein thrombosis (proximal and/or distal), non-fatal pulmonary embolism and death from all causes at Day 9 and Treatment-emergent bleeding (major, non-major clinically relevant, other non-major) at Day 8. Started Sep 2010; status: completed.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT01205932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01205932.